THC Stock Analysis: Tenet Healthcare | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 22.191m USD | 12M Return: 55.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 274M
EPS Trend: 98.4%
Qual. Beats: 3
Rev. Trend: 78.2%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Tenet Healthcare Corporation is a US-based diversified healthcare services company that operates through two main segments: Hospital Operations and Services, and Ambulatory Care. The company runs general acute care hospitals offering a broad range of inpatient, outpatient, and tertiary/quaternary services spanning cardiology, neurosurgery, organ transplants, orthopedics, trauma care, and various diagnostic and surgical specialties. Beyond its hospitals, Tenet also operates off-campus emergency departments, imaging centers, urgent care centers, micro-hospitals, ambulatory surgery centers, and surgical hospitals. Headquartered in Dallas, Texas, and founded in 1967, Tenet has been listed on the NYSE under the ticker THC since 1982 and is classified within the Health Care Facilities sub-industry, which encompasses owners and operators of hospitals and related patient care facilities. Like other for-profit hospital operators, Tenets business model combines higher-margin specialty and ambulatory services with traditional inpatient acute care, reflecting the broader industry shift toward outpatient settings.
- USPI ambulatory surgery center expansion accelerates high-margin segment growth
- Hospital labor costs and wage inflation pressure operating margins
- Same-hospital admissions and adjusted EBITDA growth signal volume recovery
| Net Income: 2.24b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 4.41 > 1.0 |
| NWC/Revenue: 10.36% < 20% (prev 14.63%; Δ -4.27% < -1%) |
| CFO/TA 0.13 > 3% & CFO 4.01b > Net Income 2.24b |
| Net Debt (11.1b) to EBITDA (5.06b): 2.19 < 3 |
| Current Ratio: 1.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (84.0m) vs 12m ago -8.53% < -2% |
| Gross Margin: 26.87% > 18% (prev 61.49%; Δ -34.63% > 0.5%) |
| Asset Turnover: 73.47% > 50% (prev 72.09%; Δ 1.39% > 0%) |
| Interest Coverage Ratio: 5.08 > 6 (EBIT TTM 4.17b / Interest Expense TTM 820.0m) |
| A: 0.07 (Total Current Assets 7.83b - Total Current Liabilities 5.57b) / Total Assets 30.7b |
| B: 0.19 (Retained Earnings 5.94b / Total Assets 30.7b) |
| C: 0.14 (EBIT TTM 4.17b / Avg Total Assets 29.7b) |
| D: 0.21 (Book Value of Equity 4.66b / Total Liabilities 22.0b) |
| Altman-Z'' = 2.28 = BBB |
| DSRI: 0.67 (Receivables 2.61b/3.70b, Revenue 21.8b/20.7b) |
| GMI: 2.29 (GM 61.49% / 26.87%) |
| AQI: 1.01 (AQ_t 0.54 / AQ_t-1 0.54) |
| SGI: 1.05 (Revenue 21.8b / 20.7b) |
| TATA: -0.06 (NI 2.24b - CFO 4.01b) / TA 30.7b) |
| Beneish M = -2.09 (Cap -4..+1) = BB |
As of August 04, 2026, the stock is trading at USD 249.99 with a total of 944,827 shares traded. Over the past week, the price has changed by +2.72%, over one month by +21.24%, over three months by +34.87% and over the past year by +55.21%.
Current recommended Stop Loss: 233.50 (which is 6.6% or 1.5 ATR below the current price).
Tenet Healthcare has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy THC.
- StrongBuy: 14
- Buy: 6
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 277.5 | 11% |
P/E Trailing = 9.9583
P/E Forward = 13.1234
P/S = 1.0174
P/B = 4.8566
P/EG = 1.9022
Revenue TTM = 21.8b USD
EBIT TTM = 4.17b USD
EBITDA TTM = 5.06b USD
Long Term Debt = 13.1b USD (from longTermDebt, last fiscal year)
Short Term Debt = 160.0m USD (from shortTermDebt, last quarter)
Debt = 13.2b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.1b USD (calculated: Debt 13.2b - CCE 2.17b)
Enterprise Value = 33.3b USD (22.2b + Debt 13.2b - CCE 2.17b)
Interest Coverage Ratio = 5.08 (Ebit TTM 4.17b / Interest Expense TTM 820.0m)
EV/FCF = 11.01x (Enterprise Value 33.3b / FCF TTM 3.02b)
FCF Yield = 9.09% (FCF TTM 3.02b / Enterprise Value 33.3b)
FCF Margin = 13.86% (FCF TTM 3.02b / Revenue TTM 21.8b)
Net Margin = 10.27% (Net Income TTM 2.24b / Revenue TTM 21.8b)
Gross Margin = 26.87% ((Revenue TTM 21.8b - Cost of Revenue TTM 16.0b) / Revenue TTM)
Gross Margin QoQ = 18.19% (prev 16.43%)
Tobins Q-Ratio = 1.08 (Enterprise Value 33.3b / Total Assets 30.7b)
Interest Expense / Debt = 6.19% (Interest Expense 820.0m / Debt 13.2b)
Taxrate = 17.88% (691.0m / 3.87b)
NOPAT = 3.42b (EBIT 4.17b * (1 - 17.88%))
Current Ratio = 1.41 (Total Current Assets 7.83b / Total Current Liabilities 5.57b)
Debt / Equity = 2.84 (Debt 13.2b / totalStockholderEquity, last quarter 4.66b)
Debt / EBITDA = 2.19 (Net Debt 11.1b / EBITDA 5.06b)
Debt / FCF = 3.66 (Net Debt 11.1b / FCF TTM 3.02b)
Total Stockholder Equity = 4.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.55% (Net Income 2.24b / Total Assets 30.7b)
RoE = 50.63% (Net Income TTM 2.24b / Total Stockholder Equity 4.43b)
RoCE = 23.77% (EBIT 4.17b / Capital Employed (Equity 4.43b + L.T.Debt 13.1b))
RoIC = 14.15% (NOPAT 3.42b / Invested Capital 24.2b)
WACC = 7.64% (E(22.2b)/V(35.4b) * Re(9.16%) + D(13.2b)/V(35.4b) * Rd(6.19%) * (1-Tc(0.18)))
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.75 | Cagr: -7.72%
[DCF] Terminal Value 77.97% ; FCFF base≈2.44b ; Y1≈2.80b ; Y5≈4.11b
[DCF] Fair Price = 590.3 (EV 61.9b - Net Debt 11.1b = Equity 50.8b / Shares 86.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.43 | EPS CAGR: 48.74% | SUE: 4.0 | # QB: 3
Revenue Correlation: 78.18 | Revenue CAGR: 1.88% | SUE: 2.42 | # QB: 1
EPS current Quarter (2026-09-30): EPS=4.64 | Chg30d=+13.15% | Revisions=+25% | Analysts=17
EPS current Year (2026-12-31): EPS=21.07 | Chg30d=+17.99% | Revisions=+25% | GrowthEPS=+25.6% | GrowthRev=+5.3%
EPS next Year (2027-12-31): EPS=20.45 | Chg30d=+15.39% | Revisions=-25% | GrowthEPS=-2.9% | GrowthRev=+0.3%
[Analyst] Revisions Ratio: +17% (up=2, down=1)